← Back to search
BIOCRYST PHARMACEUTICALS INC
DURHAM, NC, 27703
Unclaimed
Small Business
Prime contracting experience
10 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN)) | 36F79721D0166USAspending | $13,877,674 | Mar 27, 2026 | Sep 30, 2024 – Sep 29, 2025 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | BULK ORDER ORLADEYO | 36F79721D0166USAspending | $357,245 | Feb 12, 2026 | Mar 12, 2024 – Mar 11, 2025 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | PHARM - ORLADEYO | 36F79721D0166USAspending | $360,000 | Oct 1, 2025 | Oct 1, 2025 – Sep 30, 2026 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO). | 36F79721D0166USAspending | $379,939 | Aug 20, 2025 | Oct 1, 2024 – Sep 30, 2025 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | BEROTRALSTAT HCL 150MG CAP,ORAL TRADE NAME: ORLADEYO 150MG CAP | 36F79721D0166USAspending | $379,349 | Jan 27, 2025 | Sep 9, 2024 – Sep 8, 2025 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | ADVANCE DEVELOPMENT OF NEW ANTIVIRAL AGENT FOR INFLUENZA | — | $204,984,699 | Jan 10, 2025 | Jan 3, 2007 – Apr 30, 2014 |
| Prime | Department of Health and Human Services National Institutes of Health | COVID-19. TO MANUFACTURE AND EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF GALIDESIVIR A BROAD SPECTRUM, ANTIVIRAL THERAPEUTIC. | — | $2,614,652 | Aug 19, 2024 | Sep 1, 2020 – Sep 30, 2022 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | IGF::CT::IGF BIOCRYST PHARMACEUTICALS | — | $11,911,994 | Aug 13, 2024 | Mar 31, 2015 – May 31, 2021 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | PERAMIVIR, RAPIVAB FLU TREATMENT | — | $34,660,000 | Aug 8, 2022 | Sep 1, 2018 – Aug 31, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF - DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES, BASE, OPTION 1 AND OPTION 2 AWARD, 09/16/2013 - 09/15/2017 | — | $47,755,723 | Oct 19, 2021 | Sep 16, 2013 – Sep 30, 2022 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Veterans AffairsGov-sourced
- Department of Health and Human ServicesGov-sourced